mRNA Cancer Vaccines And Therapeutics Market on Track for Strong Growth, Estimated to Grow at 15.2% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the mRNA Cancer Vaccines And Therapeutics Market Through 2025?
There has been a swift expansion of the mRNA cancer vaccines and therapeutics market size over the past few years. The market is set to increase from the recorded $61.52 billion in 2024 to reach $71.22 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.8%. Factors contributing to this growth in the past are attributed to changes in lifestyle, supportive funding, favorable regulations, a robust healthcare infrastructure, and an upsurge in pipeline development.

What's the Projected Size of the Global mRNA Cancer Vaccines And Therapeutics Market by 2029?
Anticipations have been made for a swift expansion in the market size of mRNA cancer vaccines and therapeutics in the upcoming years, increasing to "$125.56 billion in 2029 with a compound annual growth rate (CAGR) of 15.2%. Various factors contribute to this predicted expansion during the forecast period, including positive results from clinical trials, increased understanding and acceptance of mRNA technology, a gap in the current medical necessities for cancer treatment, possibilities of enhanced patient outcomes, and the prospective availability of off-the-shelf options. The key market trends within the forecast period are likely to be the infiltration into novel therapeutic areas, a more individualized approach to medicine, advancements in mRNA delivery systems, multivalent mRNA vaccines and the use of artificial intelligence and machine learning in mRNA design.

View the full report here:
https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Top Growth Drivers in the mRNA Cancer Vaccines And Therapeutics Industry: What's Accelerating the Market?
The increasing incidence of cancer is anticipated to stimulate the mRNA cancer vaccine and therapeutic market's expansion in the future. Characterized by the uncontrollable proliferation and dispersion of abnormal cells that invade and damage healthy body tissues, cancer is a general term used for a variety of diseases. Sedentary lifestyles, poor nutrition, and exposure to environmental toxins contribute to the increasing prevalence of cancer. mRNA cancer vaccines and therapeutics are essential in cancer management as they provide personalized, targeted treatment methodologies that boost the immune system's efficiency in identifying and combating cancer cells, thereby improving the effectiveness of the treatment and patient outcomes. For example, in January 2023, statistics shared by the American Cancer Society, an American non-profit organization dedicated to cancer eradication, showed a significant increase in new cancer cases in the United States. In 2022, the number of new cases was approximately 1,918,030, which rose to 1,958,310 in 2023. Further, breast cancer, the most common chronic condition in the US, saw an increase from 287,850 cases in 2022 to 297,790 in 2023. Hence, it can be concluded that the rising occurrence of cancer is propelling the growth of the mRNA cancer vaccine and therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17204&type=smp

What Long-Term Trends Will Define the Future of the mRNA Cancer Vaccines And Therapeutics Market?
Major market players in the mRNA cancer vaccine and therapeutics industry are concentrating their efforts on creating cutting-edge treatments like mRNA cancer vaccines to augment effectiveness, better patient outcomes, and fulfill the rising need for potent cancer therapies. mRNA cancer vaccines, a form of immunotherapy, utilize messenger RNA to guide cells in producing distinct antigens, which in turn, galvanizes the immune system to detect and eradicate cancer cells. For example, in May 2024, the FDA gave its approval to the mRNA based cancer vaccine, WGc-043, by WestGene Biopharma, a biotechnology firm from China, for an investigational new drug application. The FDA's approval of WGc-043 signifies a major breakthrough in managing advanced EB virus-induced cancers, which have a strong connection to more than ten types of malignancies, including nasopharyngeal carcinoma, NK T-cell lymphoma, and cancers in gastric, lung, liver, esophageal, breast, and cervical areas, in addition to autoimmune diseases like multiple sclerosis and lupus.

What Are the Main Segments in the mRNA Cancer Vaccines And Therapeutics Market?
The mrna cancer vaccines and therapeutics market covered in this report is segmented -

1) By Type: Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas
2) By Application: Infectious Disease, Cancer, Other Applications
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes, Other End Users

Subsegments:
1) By Adeno Carcinomas: Lung Adenocarcinomas, Colon Adenocarcinomas, Prostate Adenocarcinomas
2) By Mucinous Carcinomas: Mucinous Ovarian Cancer, Mucinous Breast Cancer, Mucinous Colorectal Cancer
3) By Adenosquamous Carcinomas: Pancreatic Adenosquamous Carcinoma, Cervical Adenosquamous Carcinoma, Esophageal Adenosquamous Carcinoma

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17204&type=smp

Which Top Companies are Driving Growth in the mRNA Cancer Vaccines And Therapeutics Market?
Major companies operating in the mRNA cancer vaccines and therapeutics market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis SA, Sanofi AG, AstraZeneca Plc, GlaxoSmithKline Plc, Hoffmann-La Roche AG, Eli Lilly and Company, Moderna Therapeutics Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Catalent Inc., Sarepta Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Genentech Inc., Immatics Biotechnologies GmbH, CureVac N.V, Anima Biotech, Argos Therapeutics Inc.

Which Regions Will Dominate the mRNA Cancer Vaccines And Therapeutics Market Through 2029?
North America was the largest region in the mRNA cancer vaccination and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mRNA cancer vaccines and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17204

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.